Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ranolazine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: ranolazine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-001090-25 Sponsor Protocol Number: CVT 3036 Start Date*: 2004-12-28
    Sponsor Name:CV THERAPEUTICS INC
    Full Title: METABOLIC EFFICIENCY WITH RANOLAZINE FOR LESS ISCHEMIA IN NON-ST ELEVATION ACUTE CORONARY SYNDROMES A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, MULTINATIONAL, CLINICAL TRIAL TO...
    Medical condition: Non-ST Segment Elevation Acute Coronary Syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) HU (Completed) CZ (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004507-20 Sponsor Protocol Number: MEIN/11/RAN-HCM/001 Start Date*: 2012-01-19
    Sponsor Name:Menarini International Operations Luxembourg S.A.
    Full Title: RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS
    Medical condition: symptomatic hypertrophic cardiomyopathy (SHCM)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001584-77 Sponsor Protocol Number: MEIN/10/Ran-PCI/005 Start Date*: 2012-10-08
    Sponsor Name:Menarini International Operations Luxembourg S.A.
    Full Title: Effect of Ranolazine in ischemic patients with indication of staged interventional therapy
    Medical condition: Stable Angina Pectoris
    Disease: Version SOC Term Classification Code Term Level
    15.0 10007541 - Cardiac disorders 10049194 Stable angina pectoris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002789-18 Sponsor Protocol Number: RAF-01 Start Date*: 2011-11-15
    Sponsor Name:Menarini Ricerche S.p.A
    Full Title: A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY ASSESSING RANOLAZINE IN THE MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH NON...
    Medical condition: NON-PERMANENT ATRIAL FIBRILLATION
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001278-24 Sponsor Protocol Number: MEIN/10/Ran-Cad/003 Start Date*: 2011-09-02
    Sponsor Name:Menarini International Operations Luxembourg SA
    Full Title: EFFICACY OF RANOLAZINE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD)
    Medical condition: Excercise angina in patients with Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10014292 Effort angina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Completed) IE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003149-24 Sponsor Protocol Number: Ranolazine¿AOUPi/001 Start Date*: 2016-01-12
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Ranolazine in patients with post systolic thickening due to stable effort angina: a phase II, randomized, open-label, standard therapy controlled, parallel group study assessing the effects on left...
    Medical condition: Stable angina with normal ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10002383 Angina pectoris PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002273-29 Sponsor Protocol Number: GS-US-259-0133 Start Date*: 2012-03-28
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects with Chronic Stable Angina and Coronary Artery Disease with a History of Type 2 Diabetes Mellitus
    Medical condition: Angina
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10049194 Stable angina pectoris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SK (Completed) SI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-017168-17 Sponsor Protocol Number: GS-US-270-0101 Start Date*: 2010-05-31
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients with Heart Failure with Preserved Ejection Fraction
    Medical condition: Heart failure with Preserved Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    12.1 10069211 Diastolic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004865-11 Sponsor Protocol Number: IV-FLEC Start Date*: 2022-03-21
    Sponsor Name:Win Medica Pharmaceuticals S.A.
    Full Title: Comparison of the effectiveness of IntraVenous FLECainide plus oral ranolazine versus intravenous flecainide alone in the cardioversion of recent onset atrial fibrillation – a randomized, prospecti...
    Medical condition: Restoration of sinus rhythm in patients with recent AF onset
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016930-29 Sponsor Protocol Number: MeIn/09/Ran-Car/01 Start Date*: 2010-04-15
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
    Full Title: Ranolazine to treat early cardiotoxicity induced by antitumor drugs
    Medical condition: Patients who completed standard dose chemotherapy for the treatment of non-Hodgkin lymphoma or the adjuvant treatment of breast cancer or colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025322 HLGT
    9.1 10006200 PT
    9.1 10009944 PT
    9.1 10038038 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000030-35 Sponsor Protocol Number: RIMINI-Pilot Start Date*: 2013-05-08
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Reduction of Ischemic Myocardium with Ranolazine-Treatment in patients with acute myocardial Ischemia – RIMINI-Pilot-Trial
    Medical condition: CAD with acute ischemia and myocardial dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10028600 Myocardial ischaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002507-15 Sponsor Protocol Number: GS-US-259-0116 Start Date*: 2012-06-22
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneo...
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) CZ (Completed) AT (Completed) GB (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001259-37 Sponsor Protocol Number: GS-US-259-0147 Start Date*: 2012-09-06
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects with Type 2 Diabetes Mellitus.
    Medical condition: Type 2 Diabetes Mellitus.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001516-54 Sponsor Protocol Number: GS-US-259-0103 Start Date*: 2011-11-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging.
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000997-77 Sponsor Protocol Number: GS-US-259-0110 Start Date*: 2012-02-28
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002931-25 Sponsor Protocol Number: GS-US-259-0131 Start Date*: 2012-02-28
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001134-42 Sponsor Protocol Number: GS-US-291-0102 Start Date*: 2012-05-22
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A phase 2, proof of concept, randomised, placebo-controlled, parallel group study to evaluate the effect of ranolazine and dronedarone when given alone and in combination on atrial fibrillation bur...
    Medical condition: Paroxysmal Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10034039 Paroxysmal atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000805-27 Sponsor Protocol Number: MEIN/10/Ran-Did/001 Start Date*: 2012-10-23
    Sponsor Name:Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg
    Full Title: Effect of Ranolazine in Heart Failure Patients with Preserved Ejection Fraction
    Medical condition: Heart failure patients with preserved ejection fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000111-26 Sponsor Protocol Number: MEIN/10/Ran-Did/002 Start Date*: 2011-07-01
    Sponsor Name:A. MENARINI PHARMA U.K.,
    Full Title: Effect of late sodium current inhibition on MRI measured diastolic dysfunction and myocardial perfusion reserve in aortic stenosis - a proof of concept study.
    Medical condition: Aortic stenosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10007541 - Cardiac disorders 10002918 Aortic valve stenosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-004402-42 Sponsor Protocol Number: HCMRanIT001 Start Date*: 2016-10-06
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A pilot study assessing the effects of Ranolazine on coronary microvascular dysfunction in patients with hypertrophic cardiomyopathy
    Medical condition: Hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    20.1 10010331 - Congenital, familial and genetic disorders 10020204 HOCM Hypertrophic obstructive cardiomyopathy LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10020203 HOCM LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10020876 Hypertrophic obstructive cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 08:47:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA